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Margherita Massa, PHD,x Arturo Raisaro, MD,* Sergio Leonardi, MD, MHS,* Paolo Rubartelli, MD,y
Luigi Oltrona Visconti, MD,* Maurizio Ferrario, MD*
Pavia, and Genova, ItalyObjectives This study sought to evaluate whether remote ischemic post-conditioning (RIPC) could reduce
enzymatic infarct size in patients with anterior ST-segment elevation myocardial infarction undergoing
primary percutaneous coronary intervention (pPCI).Background Myocardial reperfusion injury may attenuate the beneﬁt of pPCI. In animal models, RIPC mitigates
myocardial reperfusion injury.Methods One hundred patients with anterior ST-segment elevation myocardial infarction and occluded
left anterior descending artery were randomized to pPCI þ RIPC (n ¼ 50) or conventional pPCI
(n ¼ 50). RIPC consisted of 3 cycles of 5 min/5 min ischemia/reperfusion by cuff inﬂation/deﬂation of
the lower limb. The primary endpoint was infarct size assessed by the area under the curve of
creatinine kinase-myocardial band release (CK-MB). Secondary endpoints included the following:
infarct size assessed by cardiac magnetic resonance delayed enhancement volume; T2-weighted
edema volume; ST-segment resolution >50%; TIMI (Thrombolysis In Myocardial Infarction) frame
count; and myocardial blush grading.Results Four patients (2 RIPC, 2 controls) were excluded due to missing samples of CK-MB. A total of 96 patients
were analyzed; median area under the curve CK-MB was 8,814 (interquartile range [IQR]: 5,567 to 11,325)
arbitrary units in the RIPC group and 10,065 (IQR: 7,465 to 14,004) arbitrary units in control subjects
(relative reduction: 20%, 95% conﬁdence interval: 0.2% to 28.7%; p ¼ 0.043). Seventy-seven patients
underwent a cardiac magnetic resonance scan 3 to 5 days after randomization, and 66 patients repeated
a second scan after 4 months. T2-weighted edema volume was 37  16 cc in RIPC patients and 47  22 cc
in control subjects (p ¼ 0.049). ST-segment resolution >50% was 66% in RIPC and 37% in control subjects
(p ¼ 0.015). We observed no signiﬁcant differences in TIMI frame count, myocardial blush grading, and
delayed enhancement volume.Conclusions In patients with anterior ST-segment elevation myocardial infarction, RIPC at the time of
pPCI reduced enzymatic infarct size and was also associated with an improvement of T2-weighted
edema volume and ST-segment resolution >50%. (Remote Postconditioning in Patients With
Acute Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention [PCI]
[RemPostCon]; NCT00865722) (J Am Coll Cardiol Intv 2013;6:1055–63) ª 2013 by the American
College of Cardiology Foundation
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1056ST-segment elevation myocardial infarction (STEMI) is a treated with pPCI within 6 h of symptoms onset. To test
leading cause of mortality and morbidity worldwide. Infarct
size is a key determinant of prognosis (1). Timely and
successful reperfusion, best achieved with primary percuta-
neous coronary intervention (pPCI), is effective at reducing
infarct size, preserving ventricular function, and improving
outcome (2). Nevertheless, abrupt restoration of blood
ﬂow causes a lethal injury of myocardial cells that may limit
the beneﬁt of such intervention. In pre-clinical studies,
the impact of myocardial reperfusion injury accounts
for up to 50% of the ﬁnal infarct size (3). Among strategies
aimed at limiting reperfusion injury, myocardial ischemicFrom the *Struttura Complessa Cardi
a Carattere Scientiﬁco (IRCCS) Policl
Azienda Sanitaria Locale 3 Ospedale V
Statistica Direzione Scientiﬁca, IRCC
xLaboratorio di Biotecnologie, Fond
Abbreviations
and Acronyms
anti-GP IIb/IIIa = inhibitors of
glycoprotein IIb/IIIa
ce-CMR = contrast enhanced
cardiac magnetic resonance
CI = conﬁdence interval
CK-MB = creatine kinase-
myocardial band
DE = delayed enhancement
IQR = interquartile range
LAD = left anterior
descending
LV = left ventricle/ventricular
MBG = myocardial blush
grading
pPCI = primary percutaneous
coronary intervention
RIPC = remote ischemic
post-conditioning
STEMI = ST-segment
elevation myocardial
infarction
STR = ST-segment resolution
T2W = T2-weighted
TIMI = Thrombolysis In
Myocardial Infarctionpost-conditioning, obtained by
exposing the ischemic myocar-
dium to brief periods of ischemia/
reperfusion immediately after
reperfusion, showed promising
results in both animal (4) and
small clinical studies (5–9).
However, the relevance of this
intervention in the clinical setting
remains unclear (10), and more
importantly, the safety of re-
peated balloon inﬂations to the
infarct-related artery have been
recently questioned (11,12).
In 1993, Przyklenk et al. (13)
experimentally proved that the
cardioprotective effect of myocar-
dial conditioning could also be
elicited by brief ischemia/reperfu-
sion cycles applied remotely. This
form of myocardial conditioning,
termed “remote conditioning,”
has shown protective effects (14),
even more relevant than “local”
conditioning in animals (15).
Bøtker et al. (16) tested remote
ischemic conditioning in patients
with STEMI. They observed
an improvement in myocardialsalvage, although a reduction of infarct size was only evident
in the explorative subgroup analysis of patients with
STEMI due to occluded left anterior descending (LAD)
artery.
The objective of our study was to evaluate whether remote
ischemic post-conditioning (RIPC) could safely reduce
enzymatic infarct size in patients with anterior STEMIologia, Fondazione Istituto Di Ricovero e Cura
inico San Matteo, Pavia, Italy; ySC Cardiologia,
illa Scassi, Genova, Italy; zServizio Biometria e
S Policlinico San Matteo, Pavia, Italy; and the
azione IRCCS Policlinico San Matteo, Pavia,this hypothesis, we randomized patients with occluded
LAD to pPCI þ RIPC or pPCI alone. We also evaluated
markers of reperfusion injury such as contrast-enhanced
cardiac magnetic resonance (ce-CMR) T2-weighted (T2W)
edema (17) and microvascular perfusion (angiographic
and electrocardiographic parameters).Methods
Study population. Patients ages 18 to 80 years, presenting
within 6 h of symptoms onset, with anterior STEMI, de
novo occlusion of LAD (TIMI [Thrombolysis In Myocar-
dial Infarction] ﬂow grade 0 to 1), and planned pPCI
were eligible. Anterior STEMI was deﬁned as the occur-
rence of >20 min of chest pain and ST-segment elevation
(>2 mm) in at least 2 contiguous precordial leads. Exclusion
criteria were: previous anterior STEMI or 6 months
nonanterior STEMI; Killip class IV; evidence of retrograde
ﬁlling by collaterals at coronary angiography; severe multi-
vessel coronary artery disease likely to require further
interventions before follow-up ce-CMR (4 months); known
severe abdominal aortic aneurysm (>50 mm); or severe
peripheral artery disease (class III to IV).
All patients were followed for 1 year with an ofﬁce visit at
4 months and a telephone call at 12 months. During follow-
up, we assessed vital status, recurrent myocardial infarction,
repeated myocardial revascularizations, and stroke.
Study design. This was a randomized, controlled, parallel
group, open-label trial, with blinded evaluation of the
endpoints. The study was conducted in 2 centers in Italy.
Randomization was generated via computer-assisted se-
quence of treatments with permuted blocks of varying size,
using sealed opaque envelopes. After diagnostic angiography,
eligible patients were randomized 1:1 to pPCI þ RIPC
or conventional pPCI (Fig. 1). All patients were pre-treated
with 250 mg aspirin intravenously, 300 or 600 mg
clopidogrel loading dose, and 70 IU/Kg unfractionated
heparin. Coronary angiography was performed by either
femoral or radial approach. Both groups received pPCI
according to standard techniques; the use of thrombectomy
and of inhibitors of glycoprotein IIb/IIIa (anti-GP IIb/IIIa)
was strongly encouraged. Infusion of anti-GP IIb/IIIa
was prolonged for 12 h or 18 h as appropriate. Lifelong
100 mg aspirin, angiotensin-converting enzyme inhibitors,
and beta-blockers statins were prescribed to be taken daily;
75 mg clopidogrel daily was prolonged for 12 months.Italy. This study was funded by a research grant of the Fondazione IRCCS Policlinico
San Matteo, Pavia. All authors have reported that they have no relationships relevant
to the contents of this paper to disclose.
Manuscript received April 12, 2013; revised manuscript received May 14, 2013,
accepted May 17, 2013.
Figure 1. Study Protocol
Remote ischemic post-conditioning. I ¼ ischemia; PCI ¼ percutaneous coro-
nary intervention; R ¼ reperfusion.
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1057The trial was performed according to the Declaration
of Helsinki (revised version, 1996) and the European
Guidelines for Good Clinical Practice (version 11, July
1990). The study was approved by local ethic committees.
All patients signed a written informed consent. The study
was registered with ClinicalTrials.gov (NCT00865722).
Remote ischemic post-conditioning protocol. All eligible
patients were prepared with a thigh-sized limb cuff before
arterial puncture (contralateral in case of femoral access). In the
active treatment group, the protocol was started with throm-
bectomy or balloon inﬂation, whichever occurred ﬁrst. The
lower limb was exposed to 3 cycles of ischemia/reperfusion,
each obtained by 5 min cuff inﬂation at 200 mmHg, followed
by 5min complete deﬂation (Fig. 1). Study personnel involved
in RIPC administration (nurses, fellows, or physicians) were
not involved in the assessment of the endpoints.
Enzymatic Infarct Size. Primary endpoint was the enzy-
matic infarct size assessed by the area under the curve
of creatine kinase-myocardial band (CK-MB) release
(18). Blood samples were collected before PCI, every 6 h
during the ﬁrst 48 h, and at 72 h. Blood was processed
and analyzed locally using the Abbott Architect immu-
noassay for CK-MB (Abbott Park, Illinois). Area under
the curve of CK-MB release was expressed in arbitrary
units and calculated with the trapezoidal method:
1=2
Pt¼ 72
t¼ 0 ðCKMBt0þ CKMBtxÞDt.
TIMI FRAME COUNT AND MYOCARDIAL BLUSH GRADING.
TIMI frame count and myocardial blush grading (MBG)
were evaluated 30 min after the ﬁrst balloon inﬂation or
thrombectomy in both the study arms. TIMI frame count was
the number of frames necessary to ﬁll LAD to the distal
bifurcation (19). MBG was deﬁned as previously described
(20). MBG for LAD was evaluated in left lateral projection
and compared with that of the right coronary artery.ST-SEGMENT RESOLUTION. ST-segment elevation was eval-
uated by a single investigator with lens-intensiﬁed caliper
to the nearest of 0.5 mV, 20 ms after the end of the QRS
interval. PR segment was the reference baseline. Electro-
cardiographs were collected at admission andz60 min after
reperfusion (time window  10 min). The lead with
maximal ST-segment elevation at baseline was analyzed.
ST-segment resolution (STR) was expressed as percentage
of change from baseline; cutoffs were set at 50% (STR50)
and 70% (STR70) as previously described (21).
Contrast-enhanced cardiac magnetic resonance. ACQUISITION
PROTOCOL. We performed ce-CMR 3 to 5 days after
randomization and after 4 months. We used a 1.5-T
MAGNETOM Symphony (Siemens Healthcare, Erlan-
gen, Germany) with a phased array receiver coil on the
patient chest. All subjects were placed in supine position,
and left ventricular (LV) function was assessed using
breath-hold, steady state, free precession cine-CMR.
Contiguous slices were acquired from the atrioventricular
plane to the apex in short-axis direction. Imaging param-
eters were: time to repeat¼ 46.41 ms; time of echo¼ 1.79 ms;
ﬂip angle¼ 65; slice thickness¼ 8 mm; matrix¼ 166 256;
ﬁeld of view¼ 280 to 350 mm. T2W images were acquired in
long-axis and short-axis directions from base to apex using
dark-blood T2W short tau inversion-recovery fast spin-echo
sequences. Imaging parameters were: time to repeat ¼ 750 to
2,000 ms; time of echo ¼ 69 ms; ﬂip angle ¼ 180; slice
thickness¼ 8 mm; matrix¼128 256; ﬁeld of view¼ 300 to
380 mm. Intravenous bolus of gadolinium with diethylene-
triaminepentaacetate (Magnevist, Schering, Berlin, Germany)
0.2 mmol/kg was administered. Early (z5 min) contrast
images were used to evaluate microvascular obstruction;
late images (z15 min) were used to evaluate infarct size.
Imageswere acquired in short- and long-axiswithT1-weighted
inversion-recovery sequences (inversion time: 240 to 300 ms).
IMAGE ANALYSIS. Two senior investigators computed
parameters ofﬂine (Argus, Siemens Medical solutions,
Malvern, Pennsylvania); disagreement was solved by
consensus. LV endocardial and epicardial borders were
manually traced. Each short-axis slice at both end diastole
and end systole was evaluated. Myocardial mass was calcu-
lated by multiplying myocardial volume by tissue density
(i.e., 1.05 g/ml). The hyperintense signal in T2W short tau
inversion-recovery fast spin-echo images was considered for
myocardial edema. Edema volume was computed including
signal at least 2 SD above the mean of noninfarcted
myocardium. Hyperintense signal from the blood pool was
excluded. Myocardial hemorrhage was deﬁned as a hypo-
intense signal within the area of edema. Hemorrhage was
included in the computation of T2W edema volume. Infarct
size was assessed on late-contrast images (z15 min after
gadolinium administration) by manually tracing the hyper-
intense area in each short-axis slice. Microvascular
Figure 2. Study Flowchart
CABG ¼ coronary artery bypass graft; ce-CMR ¼ contrast-enhanced cardiac magnetic resonance; CK-MB ¼ creatine kinase-myocardial band; PCI ¼ percutaneous
coronary intervention; pts ¼ patients; RIPC ¼ remote ischemic post-conditioning; STEMI ¼ ST-segment elevation myocardial infarction; TIMI ¼ Thrombolysis In
Myocardial Infarction.
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1058obstruction was deﬁned as a hypointense signal in the
infarct-related myocardium and was assessed by manually
tracing the suspected area in each short-axis slice.
Sample size. At the time of the study design, limited
clinical data were available for sample size estimation (5).
We conservatively planned to enroll a total of 100 patients
(50 per group) to obtain 92 valid patients (power: 90%,
alpha 2-sided: 5%, effect size: 0.678, corresponding to
a mean area under the curve of 326,095 in the control
group and of 241,400 in the treatment group, with
a common SD of 125,000). Two interim analyses were
performed for efﬁcacy and adaptation of sample size after
the enrollment of 40 and 60 patients, respectively (Lan-
DeMets group sequential method, O’Brien-Fleming type
alpha spending function). To preserve an overall alpha of
0.050, the p values to reject the null hypothesis of no
difference between treatments at the interim analyses was
computed to 0.0005 and 0.014, respectively, and 0.045 at
the ﬁnal analysis (22).Calculations were performed with WinLD (Programs for
Computing Group Sequential Boundaries Using the Lan-
DeMetsMethod, version 2, D.M. Reboussin, D. LDeMets,
and K. K. G. Lan, Madison, Wisconsin) and Stata (version
12, StataCorp, College Station, Texas).
Statistical analysis. Data were described as mean  SD or
median (interquartile range [IQR]) if continuous and counts
and percentages if categorical. The log-transformed primary
outcome measure was compared between groups with the
Student t test. The difference between groups was then
back-transformed and presented as ratios of control versus
treatment, with 95% conﬁdence interval (CI). Secondary
outcome measures were compared with the Fisher exact test
if categorical and either the Student t test or the Mann
Whitney U test (depending on their distribution) if
continuous. Association between continuous variables was
measured with the Spearman R. Finally, an exploratory
analysis of the primary endpoint to verify whether differ-
ential effects of treatment were present in pre-deﬁned
Table 1. Baseline Characteristics and Procedural Data
pPCI þ RIPC
(n ¼ 48)
pPCI
(n ¼ 48)
Age, yrs 61  11 56  11
Male 41 (85) 43 (90)
Body mass index, kg/m2 26  4 27  4
Family history of coronary artery disease 12 (26) 14 (30)
Hypertension 25 (54) 25 (53)
Active smokers 20 (53) 26 (54)
Dyslipidemia 14 (30) 16 (33)
Diabetes mellitus 4 (9) 7 (15)
Previous myocardial infarction 6 (12) 5 (10)
Previous percutaneous coronary
interventions
4 (8) 4 (8)
Pre-infarct angina 16 (33) 14 (29)
Baseline heart rate, beats/min 75  15 81  18
Baseline serum creatinine, mg/dl 0.96  0.27 1.01  0.22
Out of hospital cardiac arrest 3 (6) 4 (8)
Pain to balloon time, min 178 (140–230) 183 (152–251)
Vessels with critical stenosis
1-vessel disease 28 (60) 32 (67)
2-vessel disease 13 (28) 9 (19)
3-vessel disease 6 (12) 7 (14)
LAD segment of occlusion:
Proximal 24 (50) 21 (44)
Medium 20 (42) 26 (54)
Distal 4 (8) 1 (2)
Initial TIMI ﬂow grade 1 5 (11) 1 (2)
Anti-GP IIb/IIIa 48 (100) 43 (91)
Thrombectomy 37 (77) 41 (85)
Stent
Bare-metal 30 (64) 32 (68)
Drug-eluting 16 (34) 15 (32)
POBA 1 (2) 0 (0)
Contrast volume, cc 211  55 229  72
Morphine 26 (57) 25 (57)
Inotropes 2 (4) 4 (8)
Intra-aortic balloon pump 1 (2) 4 (8)
Values are mean  SD, n (%), or median (interquartile range).
anti-GP IIb/IIIa ¼ inhibitors of glycoprotein IIb/IIIa; LAD ¼ left anterior descending; POBA ¼
plain only balloon angioplasty; pPCI ¼ primary percutaneous coronary intervention; RIPC ¼
remote ischemic post-conditioning; TIMI ¼ Thrombolysis In Myocardial Infarction.
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1059subgroups of patients (age, sex, diabetes mellitus, pre-
infarction angina, morphine administration, pain to balloon
time, or presence of a multivessel disease) by ﬁtting
a multiple general linear model with inclusion of an inter-
action term between treatment and subgroup. Model
assumption was veriﬁed by inspection of residuals.
Stata was used for computation. A 2-sided p value of
<0.05 was considered statistically signiﬁcant.
Results
Patients. Between March 2009 and December 2011, 753
pPCI were performed, including 224 anterior STEMI. The
main reason for study ineligibility was severe multivessel
disease that was likely to require staged PCI (Fig. 2) (23).
We enrolled 100 patients. Four patients (2 RIPC and 2
control) had missing blood samples for primary endpoint
assessment and were excluded. The primary analysis
included 96 patients. Baseline characteristics were balanced
between the study groups (Table 1, Online Table 1). Mean
age was 58.4  10.9 years, 88% of patients were males, 12%
were diabetics, and 63% had single-vessel disease. Median
ischemia time (pain to balloon) was 182 min (IQR: 145 to
239) with no differences between the study groups. Overall,
96% of patients were treated with anti-GP IIb/IIIa and 81%
with thrombectomy. Morphine (5- to 10-mg IV boluses)
was administered before or during the procedure in 57% of
patients.
Enzymatic infarct size. The median area under the curve of
CK-MB release was 8,814 (IQR: 5,638 to 11,322) arbitrary
units RIPC patients and 10,065 (IQR: 7,510 to 13,980)
arbitrary units in control subjects (Fig. 3). This represents
a reduction of 20% (95% CI: 0.2% to 28.7%; p ¼ 0.043).
Angiographic endpoints. TIMI frame count was similar
between the RIPC and control groups. The proportion of
patients with MBG 2 or 3 was numerically higher in
patients randomized to RIPC (Table 2). Final TIMI ﬂow
grade 2 to 3 was achieved in 98% of RIPC patients and 96%
of control subjects (p ¼ 0.554).
Electrocardiographic endpoints. STR was signiﬁcantly
improved in RIPC patients than in control subjects
(Table 2). Consistent results were obtained in the RIPC
group by assessing either STR50 and STR70.
ce-CMR endpoints. During hospitalization, ce-CMR was
performed in 35 (73%) RIPC patients and 42 (87%) control
subjects. Thirty patients (87%) in the RIPC group and
36 control subjects (87%) repeated ce-CMR after 4 months.
Patients who did not perform ce-CMR had similar baseline
characteristics than those who did in terms of age, sex,
diabetes, pain to balloon time, segment of LAD occlusion,
single- versus multivessel disease, and area under the curve
of CK-MB release (data not shown).
Detailed descriptions of all the parameters are outlined in
Table 4 andOnlineTable 2. InRIPCpatients, comparedwithcontrol subjects, there was a signiﬁcant 20.6% relative
reduction of T2W edema volume (95% CI: 2.6% to 42.2%;
p ¼ 0.049) (Fig. 4). Myocardial edema correlated well with
both acute gadolinium delayed enhancement (DE) volume
(R¼ 0.88, p< 0.001) andDE volume at follow-up (R¼ 0.70,
p < 0001) (Fig. 2). We observed a numerical difference in
favor of RIPC in acute DE volume (relative reduction: 20.7%,
95% CI: –2.3% to 39.1%) and LV ejection fraction. After 4
months of follow-up, the relative reduction of DE volume in
the RIPC group was 10% (95% CI: –16.1% to 37.5%). Acute
ce-CMR DE volume (R ¼ 0.70, p < 0.001), T2W edema
volume (R ¼ 0.65, p < 0.001), and follow-up ce-CMR DE
volume (R¼ 0.66, p< 0.001) correlated well with enzymatic
Figure 3. Primary Endpoint
Area under the curve of CK-MB release, 72 h after randomization. RIPC
patients: 8,814 (IQR: 5,567 to 11,325); arbitrary units control subjects: 10,065
(IQR: 7,465 to 14,004) arbitrary units in control subjects; mean relative
reduction: 20%, 95% CI: 0.2% to 28.7%; p ¼ 0.043. Blue lines ¼ pPCI þ RIPC;
red lines ¼ pPCI; green bars ¼ 95% CI. CI ¼ conﬁdence interval; IQR ¼
interquartile range; pPCI ¼ primary percutaneous coronary intervention; other
abbreviations as in Figure 2.
Table 3. Secondary Clinical Endpoints at 12 Months
pPCI þ RIPC
(n ¼ 48)
pPCI
(n ¼ 48)
Death 0 1
Stroke 0 1
Myocardial infarction 0 1
Repeated PCI (any vessel) 3 0
CABG 1 0
CABG ¼ coronary artery bypass graft; PCI ¼ percutaneous coronary interventions;
other abbreviations as in Table 1.
Crimi et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 6 , N O . 1 0 , 2 0 1 3
RIPC of Lower Limb During pPCI Reduces Enzymatic Infarct Size in Anterior MI O C T O B E R 2 0 1 3 : 1 0 5 5 – 6 3
1060infarct size (Online Figs. 1 and 2). Based on the observed
effect size, the post-hoc power analysis to detect a difference in
acute and follow-upDE volumewere 1 – b¼ 0.46 and 1 – b¼
0.10, respectively.
Subgroup analysis. In subgroup analysis, no signiﬁcant
interaction was observed between RIPC and the pre-speciﬁed
subgroups: age (<60 vs. 60 years); sex; diabetes mellitus;
pre-infarction angina; morphine administration; pain-to-
balloon time (tertiles); and single-vessel versus multivessel
disease.
Secondary clinical endpoints and adverse events. RIPC was
successfully administered to all patients. Major adverseTable 2. Angiographic and ECG Results
pPCI þ RIPC
(n ¼ 48)
pPCI
(n ¼ 48) p Value
Final TIMI ﬂow grade
0 0 (0) 0 (0) 0.554
1 1 (2) 2 (4)
2 10 (21) 14 (29)
3 37 (77) 32 (67)
TIMI frame count, frames 21 (8) 23 (9) 0.170
MBG 0.067
Grade 0/1 5 (11) 13 (28)
Grade 2/3 39 (89) 34 (72)
STR50 28 (66) 16 (37) 0.015
STR70 12 (29) 4 (9) 0.049
Values are n (%).
ECG ¼ electrocardiograph; MBG ¼ myocardial blush grading; STR ¼ ST-segment resolution.cardiac events are outlined in Table 3. One patient died in
the control group (refractory heart failure) and none in the
RIPC group. In the control group, we observed 1 reinfarc-
tion due to subacute stent thrombosis requiring re-PCI
and 1 ischemic stroke. In the RIPC group, we observed
4 repeated coronary revascularization (3 treated with PCI,
1 with coronary artery bypass graft). Vital status was assessed
after 1-year follow-up in all but 1 patient who moved to
another country (RIPC group).Discussion
Our study shows that RIPC of the lower limb at the time of
pPCI can reduce enzymatic infarct size by 20% (95% CI:
0.2% to 28.7%) in patients with anterior STEMI and
occluded LAD undergoing pPCI within 6 h of symptoms
onset. The beneﬁt observed, though smaller than expected
and marginally signiﬁcant, was directionally consistent with
markers of myocardial reperfusion injury and successful
reperfusion such as the reduction of T2W edema volume
and the improvement of STR. Notably these effects were
obtained on top to optimal thrombus management with
thrombectomy and anti-GP IIb/IIIa.
Most of the clinical studies that explored the effect of
myocardial post-conditioning in humans, applied brief
cycles of ischemia/reperfusion to the culprit artery after
stenting. The protective effect of local post-conditioning in
STEMI patients remain unclear and recently prompted
safety concerns related to possible thrombus micro-
embolization occurring during repeated balloon inﬂations
(12) to the infarct-related artery.
To date, there are only 2 studies exploring the effects of
remote conditioning in patients undergoing pPCI (16,24).
However, this is the ﬁrst study to assess the effects of remote
post-conditioning as ischemia/reperfusion of the remote
district (the lower limb) was initiated after coronary reper-
fusion rather than before. Bøtker et al. (16) studied remote
conditioning performed during hospital transportation,
before pPCI. The primary endpoint was myocardial salvage
assessed by myocardial perfusion imaging. Myocardial
salvage was improved in remote conditioned patients, but no
Table 4. Contrast-Enhanced Magnetic Resonance Results, Acute Phase, and 4-Month Follow-Up
Acute Phase
(3 to 5 Days)
p Value
Follow-Up
(4 Months)
p Value
pPCI þ RIPC
(n ¼ 35)
pPCI
(n ¼ 42)
pPCI þ RIPC
(n ¼ 30)
pPCI
(n ¼ 36)
Days to ce-CMR 4.7  2.4 5.1  1.8 0.135 351 [179–645] 319 [203–579] 0.823
LV end-diastolic volume, ml 148  37 169  52 0.102 168  45 190  73 0.297
LV end-systolic volume, ml 84  26 102  46 0.128 93  39 107  60 0.260
LV ejection fraction, % 44  9 41  9 0.102 46  10 46  11 0.961
LV mass, g 111  26 125  38 0.098 103  23 118  37 0.158
Delayed enhancement, ml 27  14 34  19 0.113 21  12 23  13 0.500
Delayed enhancement/LV mass ratio, % 24  10 26  13 0.397 20  10 20  9 0.938
Edema, ml 37  16 47  22 0.049
Edema/LV mass ratio, % 33  11 36  15 0.291
Delayed enhancement/edema ratio, % 72  17 72  19 0.987
Presence of hemorrhage, % 19 (68) 16 (53) 0.294
Presence of microvascular obstruction, % 24 (77) 27 (75) 1.000
Values are mean  SD, n (%), or median [interquartile range], or n (%).
ce-CMR ¼ contrast enhanced cardiac magnetic resonance; LV ¼ left ventricle/ventricular; other abbreviations as in Table 1.
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observed.
Rentoukas et al. (24) tested the effects of remote condi-
tioning initiated prior to pPCI combined with morphine
administration in patients with STEMI. They enrolled 96
STEMI patients who presented within 6 h of symptom
onset who were randomly assigned to 1 of 3 reperfusion
strategies (RIPC þ pPCI, RIPC þ pPCI þ morphine,
pPCI alone). The primary endpoint of full STR was reduced
in both RIPC þ pPCI and RIPC þ pPCI þ morphine
groups.
Two relevant aspects, regarding remote ischemia/reper-
fusion protocol applied to elicitate cardioprotection, make
our study original: 1) timing; and 2) site.
Timing. Bøtker et al. (16) completed 4 cycles of remote
ischemia/reperfusion before pPCI. This protocol differs
from the original concept of post-conditioning described
by Zhao et al. (4) because it was initiated after the onset
of ischemia, but before reperfusion. This strategy could
be deﬁned as a late remote pre-conditioning. Rentoukas
et al. (24) started 3 cycles of remote ischemia/reperfusion 10
min before the estimated time of reperfusion and continued
5 min after. In fact, they termed it “remote pericondition-
ing.” We designed the present study to closely translate the
pre-clinical model (14) of remote post-conditioning into
clinical practice. We randomized patients with occluded
LAD without evidence of retrograde ﬁlling to avoid
potential confounders due to spontaneous reperfusion and/
or collateral protection. RIPC consisted of 3 cycles of
leg ischemia/reperfusion started at the time of reperfusion.
We believe that timing could have potentially relevant
implications beyond classiﬁcation. In particular, we hy-
pothesize that any circulating factor potentially mediatingthe cardioprotective effects (e.g., pH shifts, endogenous
adenosine, opioids, cytokines) has to reach the target area
(i.e., the ischemic myocardium) to mediate its effect, that
require a patent culprit artery.
Site. Both the previous studies applied ischemia/reperfusion
cycles to 1 arm. A dose-response effect, with regard to both
site and number of cycles of remote ischemia/reperfusion
was elegantly demonstrated by Loukogeorgakis et al. (25).
They explored the protective effect of remote conditioning
to mitigate endothelial ischemia/reperfusion injury of the
arm. They assessed ﬂow-mediated dilation before and
after 20 min of ischemia of the arm obtained with extrinsic
compression. A dose-response protective effect was reported
with a maximum degree of protection obtained with 3 cycles
of ischemia/reperfusion of the leg and a threshold effect of at
least 2 cycles of the arm. According to these data, we
hypothesized a dose-response effect proportional to the mass
of the remote “service” district, and we chose the lower limb,
which represents approximately 2 times the body surface and
even more tissue volume than the upper limb to elicitate
cardioprotection.
Another potentially relevant issue, compared with
previous studies, is thrombus management. In the animal
model, coronary occlusion is obtained in the absence of
thrombus. In the clinical setting, the presence of thrombus
and potential distal embolization might be important
confounders. For this reason, the use of both anti-GP IIb/
IIIa and thrombectomy (95% and 84%, respectively) were
strongly encouraged in our study. In the study by Bøtker
et al. (16), anti-GP IIb/IIIa were administered in z84% of
patients, whereas data regarding the use of thrombectomy
were not reported. In the study by Rentoukas neither anti-
GP IIb/IIIa nor thrombectomy data were reported (24).
Figure 4. Enzymatic Infarct Size and ce-CMR T2W Edema
(A) Area under the curve (AUC) of CK-MB release (log-transformed) p ¼ 0.043. (B) T2-weighted (T2W) myocardial edema volume, p ¼ 0.049. Abbreviations as in
Figures 2 and 3.
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enzymatic CK-MB release was less evident when assessed by
ce-CMR imaging. DE volume was non signiﬁcantly
reduced in RIPC patients. The reason for this difference is
unclear. There was a good correlation between enzymatic
infarct size and DE volume in both the acute phase and the
follow-up and the point estimate of the mean infarct size
reduction was similar using both enzymatic and DE volume
criteria (Fig. 4). However, DE volume was measured in 80%
of patients. So it might be possible that the lack of
difference was due to insufﬁcient power. Furthermore, the
small improvement in DE volume and LV ejection fraction
associated with RIPC in the acute phase was no longer
evident at 4 months. This ﬁnding, similar to that reported by
Bøtker et al. (16) as by other studies testing local post-
conditioning (11,12) could be the result of infarct size
shrinkage and left ventricle remodeling that further reduced
power during follow-up.
The results of secondary endpoints support the hypothesis
that RIPC might reduce infarct size by limiting myocardial
reperfusion injury.
RIPC was associated with a reduction of myocardial
T2W edema volume, a potential marker of reperfusion
injury (17). Edema usually starts during the ischemic phase
and expands in the interstitial space during reperfusion, thus
increasing hydrostatic pressure, causing capillary compres-
sion and potentially limit tissue perfusion. Myocardial
edema could have an indirect negative effect on myocardium
and contribute to the pathogenesis of reperfusion injury
(26,27).
RIPC signiﬁcantly improved STR. STR has been
proposed as a marker of efﬁcient microvascular reperfusion,
and it yields prognostic information beyond that provided bycoronary TIMI ﬂow grade. Several studies have shown
a consistent relationship between STR and subsequent
mortality (28).
RIPC was also associated with a trend of improvement
in MBG, whereas no difference was found in TIMI
frame count. MBG has been proposed as a more efﬁcient
marker of successful microvascular reperfusion than TIMI
ﬂow grade and TIMI frame count and has been positively
associated with long-term mortality (20) in STEMI
patients.
RIPC was easy to perform, inexpensive, and well toler-
ated. We observed no adverse effect related to RIPC during
hospitalization. No patient died in the RIPC group at
12 months. During follow-up, we observed 4 repeated
revascularizations in RIPC patients. These clinical events
were due to in-stent restenosis following bare-metal stent
implantation, so the relationship with the study treatment is
unlikely.
Study limitations. The study was not double-blinded.
However, to limit potential source of bias, all patients were
prepared with tight-sized cuffs, and the endpoints were
evaluated by investigators blinded to treatment allocation.
The results reﬂect a selected population of patients
with STEMI. Moreover, the ratio between patients screened
and randomized was higher and the period of enrollment
was longer than originally planned. However, no major
changes were observed in the managements of patients with
STEMI during this time, so it is likely that the impact of
this aspect is limited.
We did not assess the area at risk, nevertheless we
enrolled only patients with occluded LAD and the segment
of occlusion, a surrogate of area at risk, was not different
between the groups.
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ence in DE volume both in the acute phase and at follow-up.
Conclusions
RIPC of the lower limb at the time of primary PCI in
patients with anterior STEMI due to occluded LAD within
6 h of symptoms onset, reduces enzymatic infarct size and is
associated with the improvement of markers of myocardial
reperfusion injury (T2W edema volume) and microvascular
reperfusion (STR). Given its excellent feasibility, safety
proﬁle, and minimal costs, these encouraging results warrant
further investigations.
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